[Pe-036] English Poster Session 036「Muscle diseases」

[Pe-036-5] COMET: safety of switching to avalglucosidase alfa (AVA) in late-onset Pompe disease (LOPD)

Mitsunobu Ikeda¹, Díaz-Manera Jordi², Kishnani Priya S.³, Ladha Shafeeq⁴, Miossec Patrick⁵, Armstrong Nicole⁵, Thibault Nathan⁵, Periquet Magali⁵, Tammireddy Swathi⁵, Dimachkie Mazen M.⁶, Schoser Benedikt⁷, on behalf of the COMET Investigator Group (1.Sanofi K.K., Japan, 2.John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK, 3.Duke University Medical Center, Durham, NC, USA, 4.Gregory W. Fulton ALS and Neuromuscular Center, Barrow Neurological Institute, Phoenix, AZ, USA, 5.Sanofi, USA, 6.University of Kansas Medical Center, Department of Neurology, Kansas City, KS, USA, 7.Friedrich-Baur-Institute, Department of Neurology, LMU Klinikum Munchen, Munchen, Germany)